These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18184868)

  • 61. Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance.
    Raoux D; Duband S; Forest F; Trombert B; Chambonnière ML; Dumollard JM; Khaddage A; Gentil-Perret A; Péoc'h M
    Neuropathology; 2010 Jun; 30(3):232-40. PubMed ID: 19925562
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Characterization of genomic alterations in primary central nervous system lymphomas.
    Zorofchian S; El-Achi H; Yan Y; Esquenazi Y; Ballester LY
    J Neurooncol; 2018 Dec; 140(3):509-517. PubMed ID: 30171453
    [TBL] [Abstract][Full Text] [Related]  

  • 63. SHP-1 expression in primary central nervous system B-cell lymphomas in immunocompetent patients reflects maturation stage of normal B cell counterparts.
    Sugita Y; Tokunaga O; Nakashima A; Shigemori M
    Pathol Int; 2004 Sep; 54(9):659-66. PubMed ID: 15363033
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Emerging insights into origin and pathobiology of primary central nervous system lymphoma.
    You H; Wei L; Kaminska B
    Cancer Lett; 2021 Jul; 509():121-129. PubMed ID: 33766752
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Hypoxia-associated protein expression in primary central nervous system diffuse large B-cell lymphoma: does it predict prognosis?
    Kim JA; Kim SJ; Do IG; Jin J; Nam DH; Ko YH; Kim K; Kim WS
    Leuk Lymphoma; 2011 Feb; 52(2):205-13. PubMed ID: 21281236
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Analysis of genomic copy number alterations of malignant lymphomas and its application for diagnosis].
    Tagawa H
    Gan To Kagaku Ryoho; 2007 Jul; 34(7):975-82. PubMed ID: 17637530
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mutational analysis of primary central nervous system lymphoma.
    Bruno A; Boisselier B; Labreche K; Marie Y; Polivka M; Jouvet A; Adam C; Figarella-Branger D; Miquel C; Eimer S; Houillier C; Soussain C; Mokhtari K; Daveau R; Hoang-Xuan K
    Oncotarget; 2014 Jul; 5(13):5065-75. PubMed ID: 24970810
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Treatment outcome and prognostic factors in PCNSL.
    Niparuck P; Boonsakan P; Sutthippingkiat T; Pukiat S; Chantrathammachart P; Phusanti S; Boonyawat K; Puavilai T; Angchaisuksiri P; Ungkanont A; Chuncharunee S; Atichartakarn V
    Diagn Pathol; 2019 Jun; 14(1):56. PubMed ID: 31189479
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Primary central nervous system lymphoma in Korea: comparison of B- and T-cell lymphomas.
    Choi JS; Nam DH; Ko YH; Seo JW; Choi YL; Suh YL; Ree HJ
    Am J Surg Pathol; 2003 Jul; 27(7):919-28. PubMed ID: 12826884
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
    Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
    Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin.
    Lin CH; Kuo KT; Chuang SS; Kuo SH; Chang JH; Chang KC; Hsu HC; Tien HF; Cheng AL
    Clin Cancer Res; 2006 Feb; 12(4):1152-6. PubMed ID: 16489068
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.
    Baraniskin A; Kuhnhenn J; Schlegel U; Chan A; Deckert M; Gold R; Maghnouj A; Zöllner H; Reinacher-Schick A; Schmiegel W; Hahn SA; Schroers R
    Blood; 2011 Mar; 117(11):3140-6. PubMed ID: 21200023
    [TBL] [Abstract][Full Text] [Related]  

  • 73. TP53 hotspot mutations are predictive of survival in primary central nervous system lymphoma patients treated with combination chemotherapy.
    Munch-Petersen HD; Asmar F; Dimopoulos K; Areškevičiūtė A; Brown P; Girkov MS; Pedersen A; Sjö LD; Heegaard S; Broholm H; Kristensen LS; Ralfkiaer E; Grønbæk K
    Acta Neuropathol Commun; 2016 Apr; 4():40. PubMed ID: 27101868
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Promoter methylation attenuates SHP1 expression and function in patients with primary central nervous system lymphoma.
    Liu J; Wang Y; Sun X; Ji N; Sun S; Wang Y; Liu F; Cui Q; Wang C; Liu Y
    Oncol Rep; 2017 Feb; 37(2):887-894. PubMed ID: 27959415
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Bioinformatic validation identifies candidate key genes in diffuse large-B cell lymphoma.
    Huang Q; Liu F; Shen J
    Per Med; 2019 Jul; 16(4):313-323. PubMed ID: 31331250
    [No Abstract]   [Full Text] [Related]  

  • 76. Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma.
    Sung CO; Kim SC; Karnan S; Karube K; Shin HJ; Nam DH; Suh YL; Kim SH; Kim JY; Kim SJ; Kim WS; Seto M; Ko YH
    Blood; 2011 Jan; 117(4):1291-300. PubMed ID: 21088137
    [TBL] [Abstract][Full Text] [Related]  

  • 77. STAT3 Activation Is Associated with Interleukin-10 Expression and Survival in Primary Central Nervous System Lymphoma.
    Yang X; Wang Y; Sun X; Bai X; Cui Q; Zhu H; Qian J; Chen Y; Sun S; Ji N; Liu Y
    World Neurosurg; 2020 Feb; 134():e1077-e1084. PubMed ID: 31778838
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Activated B-cell immunophenotype might be associated with poor prognosis of primary central nervous system lymphomas.
    Bhagavathi S; Sharathkumar A; Hunter S; Sung L; Kanhere R; Venturina MD; Wilson JD
    Clin Neuropathol; 2008; 27(1):13-20. PubMed ID: 18257470
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Tumor and Cerebrospinal Fluid microRNAs in Primary Central Nervous System Lymphomas.
    Zajdel M; Rymkiewicz G; Sromek M; Cieslikowska M; Swoboda P; Kulinczak M; Goryca K; Bystydzienski Z; Blachnio K; Ostrowska B; Borysiuk A; Druzd-Sitek A; Walewski J; Chechlinska M; Siwicki JK
    Cancers (Basel); 2019 Oct; 11(11):. PubMed ID: 31731456
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Identification of ADGRE5 as discriminating MYC target between Burkitt lymphoma and diffuse large B-cell lymphoma.
    Kleo K; Dimitrova L; Oker E; Tomaszewski N; Berg E; Taruttis F; Engelmann JC; Schwarzfischer P; Reinders J; Spang R; Gronwald W; Oefner PJ; Hummel M
    BMC Cancer; 2019 Apr; 19(1):322. PubMed ID: 30953469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.